Most-Downgraded StocksMost-DowngradedNASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $219.72 -11.46 (-4.96%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$220.10 +0.38 (+0.17%) As of 10/2/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ALNY alerts:Sign Up Key Stats Today's Range$219.40▼$231.3650-Day Range$205.48▼$288.4152-Week Range$197.81▼$495.55Volume1.66 million shsAverage Volume1.31 million shsMarket Capitalization$29.40 billionP/E Ratio40.84Dividend YieldN/APrice Target$366.90Consensus RatingModerate Buy Company Overview Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis. The company also develops investigational RNAi medicines for diseases affecting the liver, cardiovascular system, central nervous system, and other areas. The company serves patients and healthcare providers through commercial operations and partnerships in the United States and international markets. Alnylam has entered collaborations with pharmaceutical companies to support the development, manufacturing, and commercialization of certain products. Yvonne Greenstreet has served as Alnylam’s chief executive officer since 2022.AI Generated. May Contain Errors. Read More Alnylam Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreALNY MarketRank™: Alnylam Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 168th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 16 buy ratings, 6 hold ratings, and no sell ratings.Upside PotentialAlnylam Pharmaceuticals has a consensus price target of $366.90, representing about 67.0% upside from its current price of $219.72.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth44.56% Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow by 44.56% in the coming year, from $6.71 to $9.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is 40.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is 40.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 36.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alnylam Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.42% of the float of Alnylam Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.13.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 13.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.21 News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Alnylam Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 15 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Stock News HeadlinesSecurities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzOctober 2 at 5:40 PM | globenewswire.comAlnylam Pharmaceuticals, Inc. - Depositary receipt price target increased by 10.26% to R$105.31October 2 at 9:26 AM | msn.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CMSeptember 29, 2026 | marketscreener.comMAlnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansformSeptember 28, 2026 | seekingalpha.com18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.September 28, 2026 | fool.comAlnylam Needs Stronger Amvuttra Execution To Justify More UpsideSeptember 26, 2026 | seekingalpha.comAquaBounty Technologies (NASDAQ:AQB) versus Alnylam Pharmaceuticals (NASDAQ:ALNY) Head-To-Head ComparisonSeptember 23, 2026 | americanbankingnews.comSee More Headlines ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $397.65 at the start of the year. Since then, ALNY stock has decreased by 44.7% and is now trading at $219.72. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. The company's quarterly revenue was up 66.9% compared to the same quarter last year. Read the conference call transcript. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional investors include Versant Capital Management Inc and Burkett Financial Services LLC. Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Tolga Tanguler, Pushkal Garg, Kevin Joseph Fitzgerald, Michael W Bonney, Melissa Mclaughlin, Amy W Schulman, David E I Pyott, Dennis A Ausiello, Colleen F Reitan and Phillip A Sharp. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AUO (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings7/30/2026Today10/03/2026Investor update10/26/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALNY's financial health is in the Red zone, according to TradeSmith. ALNY has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,770Year Founded2002Price Target and Rating Average Price Target for Alnylam Pharmaceuticals$366.90 High Price Target$489.00 Low Price Target$256.00 Potential Upside/Downside+67.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$5.38 Trailing P/E Ratio40.84 Forward P/E Ratio32.75 P/E GrowthN/ANet Income$313.75 million Net Margins15.26% Pretax Margin15.95% Return on Equity84.93% Return on Assets14.30% Debt Debt-to-Equity Ratio0.75 Current Ratio3.05 Quick Ratio2.99 Sales & Book Value Annual Sales$3.71 billion Price / Sales7.92 Cash Flow$2.80 per share Price / Cash Flow78.58 Book Value$5.97 per share Price / Book36.80Miscellaneous Outstanding Shares133,810,000Free Float132,658,000Market Cap$29.40 billion OptionableOptionable Beta0.28 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ALNY) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
